NCT02318836View on ClinicalTrials.gov

Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Liver Failure
Interventions
DRUG

Lofexidine Hydrochloride (HCl) tablets

Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT02318836 - Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects | Biotech Hunter | Biotech Hunter